PemOla

A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden > 4 mutations/Mb

Research summary

Metastatic pancreatic ductal adenocarcinoma (mPDA) is an aggressive form of cancer with very poor outcomes. It is generally treated with traditional chemotherapy but even with chemotherapy, average life expectancy of patients with mPDA is under 1 year. In the search for treatments to improve life expectancy for cancer patients, immunotherapy drugs that boost the immune system, like pembrolizumab are increasingly being used. Unfortunately, so far they have not helped people suffering from mPDA. Olaparib works by preventing cancer cells repairing themselves. Combining olaparib with pembrolizumab may be a better way of boosting the immune system. We think that the people most likely to benefit from combining these two drugs are those mPDA patients whose tumours contain very high amounts of genetic changes that will help the body’s immune system seek out and kill the cancer cells more easily.

 

PemOla will investigate a new immunotherapy approach in a subgroup of patients with mPDA and TMB >4 mutations/Mb, or DNA mismatch repair deficiency (dMMR), determined at gene or protein (MSI-H) level. The trial is a phase II single arm open label, non-randomised, multicentre study. This trial will assess the Objective Response Rate defined as the proportion of patients with a complete response or partial response to treatment according to RECIST methodology. This is a multi-centre trial and we plan to include up to 20 UK centres within this trial. The recruitment target is 20 participants. The trial duration consists of a 28-day screening period, treatment until disease progression or up to 2 years, followed by an end of treatment assessment and follow-up until death, loss to follow-up or trial closure.

Main inclusion criteria

  • Aged ≥ 18 years old
  • Written informed consent
  • Histologically or cytologically confirmed PDA
  • Confirmation that the PDA has TMB >4 mutations/Mb, or dMMR gene mutation, or MSI-H by IHC
  • Radiologically confirmed stage 4 mPDA, with measurable disease
  • Received no more than 1 prior systemic therapy regimen for unresectable (stage 3 or 4) PDA is allowed
  • Measurable disease which has not been irradiated in prior radiotherapy
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
  • Life expectancy >12 weeks from the date of screening assessment
  • Adequate bone marrow function:
    • Absolute neutrophil count (ANC) ≥1.5 x 109 /L
    • Haemoglobin (Hb) ≥ 90 g/L
    • Platelets ≥100 x 109 /L
  • Adequate liver function:
    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 x upper limit of normal range (ULN), or <5 x ULN in the presence of liver metastases
    • Total bilirubin <1.5 x ULN
  • Adequate renal function defined as a calculated creatinine clearance by Cockcroft- Gault of ≥50 mL/min

Main exclusion criteria

  • Patients with resectable or locally advanced PDA
  • Other invasive malignancies diagnosed within the last 2 years which have not been treated with curative intent
  • Prior immune checkpoint inhibitors or PARP inhibitors. This includes any prior therapy with an anti-PD-1, or anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g, CTLA-4, OX 40, CD137)
  • Requirement for non-physiological dose of daily oral steroids, or regular use of any other immunosuppressive agents; prednisolone dose of < 10mg (or equivalent steroid dose) is allowed. Use of inhaled or topical steroids is allowed.
  • Significant acute or chronic medical or psychiatric condition, disease or laboratory abnormality, which in the judgment of the investigator would place the patient at undue risk or interfere with the trial. Examples include, but are not limited to:
    • A history of chronic obstructive pulmonary disease, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, cystic fibrosis or bronchiectasis affecting pulmonary function, causing breathlessness at rest
    • Uncontrolled ischaemic heart or other cardiovascular event (myocardial infarction, new angina, stroke transient ischaemic attack, or new congestive cardiac failure) within the last 2 months
    • Stable but significant cardiovascular disease defined by heart failure (New York Heart Association Functional Classification III or IV) or frequent angina
    • Presence of active infection
    • Cirrhotic liver disease, known HIV, chronic active or acute hepatitis B, or hepatitis C
    • History of severe allergy or hypersensitivity reactions
    • Autoimmune disease requiring chronic use of immunosuppressive agents.
    • Replacement therapy using physiological doses for adrenal or pituitary insufficiency is allowed.
    • Known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder that have undergone potentially curative therapy are not excluded.
    • Has known brain metastases 
    • Has myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML.
  • Women who are pregnant, or plan to become pregnant or are lactating.
  • Women of child-bearing potential and male patients who are unwilling to adhere to the contraception requirement from informed consent until the last dose of the trial treatment and for 120 days after the last dose of trial treatment.
  • Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication.
  • Concomitant use of known potent CYP3A4 inhibitors and inducers. Restrictions relating to concomitant medications are described in section 10.9 of the protocol. Please consider washout periods.
  • Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to screening.
  • Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
  • Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
  • Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
  • Participant received colony-stimulating factors (e.g., granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM CSF] or recombinant erythropoietin) within 28 days prior to the first dose of study intervention.
  • Is currently participating in, has participated in a study of an investigational agent, or has used an investigational device within 4 weeks prior to the first dose of study intervention.
  • Participant has persistent toxicities (>CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia.
  • Has had an allogenic tissue/solid organ transplant
  • Judgment by the Investigator that the patient should not participate in the trial.

Funders and sponsors

Chief investigator

Chief Investigator: Dr Pippa Corrie

Contact details

Email address: [email protected]